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INTRODUCTION:  Phlegmasia  caerulea  dolens  (PCD)  is  a  clinical  syndrome  caused  by venous  obstruction
leading  to  peripheral  limb  ischaemia.  It can  ultimately  lead to venous  gangrene,  amputation  or  death  in
25%  of  cases.
PRESENTATION  OF CASE:  A 52-year-old  man  with  a background  of  myeloma  developed  PCD  secondary  to
an  obstructing  plasmacytoma  and  left femoral  vein  deep  vein  thrombosis  (DVT).  These  were  treated  with
combined  radiotherapy  and  anticoagulation,  with  resolution  of  the patient’s  symptoms.  His  recovery  was
complicated  by  the  development  of heparin-induced  thrombocytopenia  (HIT)  and cutaneous  vasculitis.
DISCUSSION: Both  plasmacytoma  and  DVT  are recognised  complications  of  myeloma.  This is,  to our  knowl-
edge,  the ﬁrst description  of  these  phenomena  in  combination  causing  PCD.  The  combination  of  venous
stasis  from  the  obstructing  plasmacytoma  and  hypercoagulability  from  the  underlying  myeloma  may
have  contributed  to clot  formation.  A multifaceted  treatment  approach  was  required  which  aimed  at
improving  venous  ﬂow  via radiotherapy  to the  plasmacytoma  and  dissolving  the  obstructing  clot  with
anticoagulant  therapy.
CONCLUSION: PCD  has  a high  mortality  and  morbidity.  Recognition  is important  to  avoid  an  incorrect
diagnosis  of arterial  occlusion  and  inappropriate  surgical  intervention.  Treatment  must  be  focused  on
removing  the  offending  causes.
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. Introduction
Phlegmasia caerulea dolens (PCD) is caused by an obstructing
enous lesion leading to pain, swelling and ultimately signs of
cute arterial ischaemia. This is due to increased compartmental
ressures causing secondary arterial compromise. PCD has a high
orbidity and mortality. In addition, the clinical presentation of
CD can be confused with acute limb ischaemia, which may  lead to
nappropriate surgical intervention and patient harm. Despite its
everity, management of the condition has not improved greatly
ver the last few decades. Treatment focuses on anticoagulation of
ny deep vein thrombosis (DVT) and in select cases intra-arterial
hrombolysis. Elevation and ﬂuid resuscitation also have a role in
atient management. Severe cases may  require limb amputation.∗ Corresponding author at: 96 Wolfa Street, Derby DE22 3SD, United Kingdom.
el.:  +44 7590054085.
E-mail addresses: dr.doleman@gmail.com (B. Doleman),
umar.abayesakara@nhs.net (K. Abayasekara), james.kirk1@nhs.net (J. Kirk).
210-2612 © 2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associate
ttp://dx.doi.org/10.1016/j.ijscr.2013.07.010e Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. 
2. Presentation of case
A  52-year-old male with a background of left pelvic plasmacy-
toma and myeloma presented with acute left leg pain and swelling.
On examination, the left leg was cold, swollen with blue dis-
colouration and loss of distal sensation. In addition, distal pulses
were absent on Doppler examination. A junior vascular surgeon
reviewed the patient and a diagnosis of acute limb ischaemia was
made. Therefore, the patient underwent a computerised tomogra-
phy (CT) angiogram, which demonstrated no arterial occlusion,
although did demonstrate a large soft tissue mass encasing the
left common iliac vessels. A subsequent ultrasound (US) of the
left leg demonstrated gross subcutaneous oedema with a non-
compressible femoral vein, no colour ﬂow on Doppler and no ﬂow
on calf compression consistent with a left femoral DVT. The patient
showed no symptoms or signs of pulmonary embolism and his
observations were stable.
Following review of a recent magnetic resonance image (MRI)
scan (Fig. 1), the pelvic plasmacytoma was  implicated in obstruc-
ting the venous outﬂow around the common iliac vein. In view of
the signs on examination, US and CT angiogram ﬁndings, a diag-
Open access under CC BY license.nosis of phlegmasia caerulea dolens (PCD) was  made secondary to
pelvic plasmacytoma and left femoral DVT. The patient was com-
menced on subcutaneous low molecular weight heparin (LMWH),
leg elevation and received radiotherapy for the plasmacytoma,
s Ltd. Open access under CC BY license.
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Fig. 1. Magnetic resonance imaging of the pelvis demonstrating plasmacytoma (red
arrow) and encased left common iliac vein (blue arrow).
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(ig. 2. Patient’s left limb demonstrating residual swelling and features of cutaneous
asculitis (lateral view).
hich improved the patient’s symptoms. However, the patient’s
ecovery was complicated by the development of heparin-induced
hrombocytopenia (HIT). He was therefore changed from LMWH  to
ivaroxaban with further clinical improvement.
In addition to the development of HIT, the patient began toevelop a vasculitic rash on his lower limbs. A dermatologist
eviewed the patient and a diagnosis of cutaneous vasculitis was
ade secondary to myeloma (Figs. 2 and 3). He continued to
ig. 3. Patient’s left limb further showing vasculitic rash and residual swelling
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improve and was  discharged home following a four-week period
in hospital on long-term anticoagulation with Rivaroxaban.
3. Discussion
PCD literally translates as painful blue oedema. It may result
from a large deep vein thrombosis or other occlusive process
and causes pain, oedema and signs of peripheral ischaemia. It
is differentiated from the less severe phlegmasia alba dolens
where collateral vein patency maintains circulation and reduces
ischaemia. PCD has a mortality of 25% with an amputation rate
of 12–25%.1 It is more common in females and more commonly
affects the left leg.1 In severe cases, it can lead to venous gan-
grene, hypovolaemic shock and the need for limb amputation
secondary to arterial compromise. This is thought to be sec-
ondary to an increase in compartment pressures to 16–17 times
normal.2
PCD is commonly associated with malignancy, obstructing
lesions, thrombophilia and less commonly the placement of inferior
caval ﬁlters. The initial blockage of the venous system leads to the
presenting symptoms of pain and swelling. This then progresses to
tissue ischaemia and resulting gangrene. Ultimately, this may lead
to massive pulmonary embolism or death in a signiﬁcant propor-
tion of patients. Our case may  well have been multi-factorial, with
the combination of plamacytoma and deep vein thrombosis con-
tributing to an obstructed venous system. Indeed, Virchow’s triad
dictates that venous stasis, endothelial injury and hypercoagulabil-
ity contribute to blood clot formation. Malignant conditions such as
myeloma are well known to cause hypercoagulable states,3 which
in combination with the venous stasis that occurred due to the
encased iliac veins from the plamacytoma, may  have contributed
to colt formation in our case.
Despite advances in technology, little progress has been made
in the management of PCD over the last 30 years.1 Large-scale tri-
als are difﬁcult to conduct. Some success has been shown with
the use of anticoagulation, elevation and ﬂuid resuscitation in one
small case series.4 A selected group of patients may also respond
to thrombolysis, reducing the need for amputation.5,6 In extreme
cases, surgical amputation is required. In our case, the plasmacy-
toma was treated with radiotherapy to reduce soft tissue bulk and
improve blood ﬂow in the encased vein. Furthermore, the likely
femoral DVT was treated with anticoagulation. However, the onset
of HIT required alternative anticoagulation with Rivaroxaban with
good success. These newer anticoagulants may offer an alternative
treatment to patients with HIT and have been shown to be effective
in DVT treatment in a previous large-scale randomised controlled
trial.7
4. Conclusion
Phlegmasia caerulea dolens is a rare manifestation of an
obstructed venous system with a high morbidity and mortality.
Diagnosis may  be difﬁcult as loss of distal pulses may be confused
with acute arterial ischaemia leading to inappropriate surgical
intervention. In the case we present here, successful combina-
tion treatment was  aimed at anticoagulation to reduce clot size
and radiotherapy to reduce plasmacytoma bulk. Due to the onset
of HIT, successful anticoagulation was achieved with Rivaroxa-
ban.Conﬂict of interest
No conﬂicts on interest or funding received in the production of
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